Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies

Area and reason for the study: Extensive-stage small-cell lung cancer (ES-SCLC). To analyze the effect of trilaciclib on Chinese and Caucasian patients. Approach taken, including aspects such as the sample size: This pooled analysis included one study in China and three studies in western countries, and the overall sample size was 325. Overall result: Trilaciclib provides protection from CIM. General significance of the findings: The consistent efficacy of trilaciclib can be observed from pooled data across different treatment lines. All information should be accessible to a nonexpert audience.